North America Intravenous Immunoglobulin Market Size and Forecasts (2020 - 2030), Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (IgG, IgA, IgM, and Others), Application (Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Idiopathic Thrombocytopenic Purpura, Multifocal Motor Neuropathy, Hypogammaglobulinemia, Guillain-Barre Syndrome, Specific Antibody Deficiency, Inflammatory Myopathies, Myasthenia Gravis, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Country (US, Canada, and Mexico)
The North America intravenous immunoglobulin market size was valued at US$ 5.042 Bn in 2022 and is expected to reach US$ 8.747 Bn by 2030; it is estimated to record a CAGR of 7.1% from 2022 to 2030. The North America intravenous immunoglobulin market growth is primarily driven by increase in use of immunoglobulins and rising prevalence of immunodeficiency diseases
New Product Launches and Approvals Opportunity for Growth of Intravenous Immunoglobulin Market
In recent years, there have been various developments in the intravenous immunoglobulin market in North America. Market players have been launching new products and seeking regulatory approvals for their offerings. In April 2023, Takeda Pharmaceutical Company Limited, an R&D-driven biopharmaceutical leader, received a supplemental Biologics License Application (sBLA) approval from the US Food and Drug Administration (FDA) to expand the use of HYQVIA to treat primary immunodeficiencies (PI) in children belonging to the age group of 2–16 years. Only HYQVIA's subcutaneous immune globulin (ScIG) infusion allows for monthly administration. In 2022, Health Canada approved HyQvia, a new Immunoglobulin (IG) treatment for Canadians with immune deficiencies. In February 2021, Pfizer Inc. received an sBLA approval for PANZYGA (10% liquid intravenous immunoglobulin preparation) to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
Type-Based Insights
The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022–2030.
Application-Based Insights
Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022–2030.
Distribution Channel -Based Insights
Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022–2030.
End User - Based Insights
Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022–2030.
Patients with autoimmune diseases are treated with intravenous immunoglobulins. Autoimmune diseases are conditions wherein the immune system accidentally attacks its own tissues or cells. Chronic inflammation, and organ and system damage result from this aberrant immune reaction against healthy cells. Fatigue, joint pain, muscle weakness, skin rashes, and neurological disturbances are a few of the typical signs and symptoms of autoimmune diseases. Symptoms of autoimmune diseases such as Guillain-Barrй syndrome (GBS), myasthenia gravis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (LE), and immune thrombocytopenia (ITP) can be alleviated with the IVIG therapy. Benefits of this therapy include the rapid relief of symptoms and long-lasting effects, leading to improved quality of life among patients.
According to the Intermountain Healthcare, autoimmune and immune-mediated diseases and conditions affect 23.5–50 million Americans. According to the Centers for Disease Control and Prevention, rheumatoid arthritis (RA) is the most prevalent type of autoimmune arthritis, and 1 in 4 adults in the US has arthritis. As per the Myasthenia Gravis Foundation of America, Inc., the prevalence of myasthenia gravis (MG) is estimated at 14–20 per 100,000 of the US population. In Canada, the incidence of MG is estimated to be 23 per 1 million person-years, with a prevalence of 263 per 1 million people, and the numbers have been stable over the past few decades.
Increase in Use of Immunoglobulins Bolsters North America Intravenous Immunoglobulins Market
Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is rising with the surging use of these antibodies for treating various conditions.
Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the leading companies operating in the intravenous immunoglobulin market.
A few of the major primary and secondary sources referred to while preparing the report on the North America intravenous immunoglobulin market are the Myasthenia Gravis Foundation of America, Journal of Allergy and Clinical Immunology, Genetic and Rare Diseases Information Center, Immune Deficiency Foundation, GBS Foundation, Centers for Disease Control and Prevention
New Product Launches and Approvals Opportunity for Growth of Intravenous Immunoglobulin Market
In recent years, there have been various developments in the intravenous immunoglobulin market in North America. Market players have been launching new products and seeking regulatory approvals for their offerings. In April 2023, Takeda Pharmaceutical Company Limited, an R&D-driven biopharmaceutical leader, received a supplemental Biologics License Application (sBLA) approval from the US Food and Drug Administration (FDA) to expand the use of HYQVIA to treat primary immunodeficiencies (PI) in children belonging to the age group of 2–16 years. Only HYQVIA's subcutaneous immune globulin (ScIG) infusion allows for monthly administration. In 2022, Health Canada approved HyQvia, a new Immunoglobulin (IG) treatment for Canadians with immune deficiencies. In February 2021, Pfizer Inc. received an sBLA approval for PANZYGA (10% liquid intravenous immunoglobulin preparation) to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
Type-Based Insights
The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022–2030.
Application-Based Insights
Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022–2030.
Distribution Channel -Based Insights
Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022–2030.
End User - Based Insights
Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022–2030.
Patients with autoimmune diseases are treated with intravenous immunoglobulins. Autoimmune diseases are conditions wherein the immune system accidentally attacks its own tissues or cells. Chronic inflammation, and organ and system damage result from this aberrant immune reaction against healthy cells. Fatigue, joint pain, muscle weakness, skin rashes, and neurological disturbances are a few of the typical signs and symptoms of autoimmune diseases. Symptoms of autoimmune diseases such as Guillain-Barrй syndrome (GBS), myasthenia gravis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (LE), and immune thrombocytopenia (ITP) can be alleviated with the IVIG therapy. Benefits of this therapy include the rapid relief of symptoms and long-lasting effects, leading to improved quality of life among patients.
According to the Intermountain Healthcare, autoimmune and immune-mediated diseases and conditions affect 23.5–50 million Americans. According to the Centers for Disease Control and Prevention, rheumatoid arthritis (RA) is the most prevalent type of autoimmune arthritis, and 1 in 4 adults in the US has arthritis. As per the Myasthenia Gravis Foundation of America, Inc., the prevalence of myasthenia gravis (MG) is estimated at 14–20 per 100,000 of the US population. In Canada, the incidence of MG is estimated to be 23 per 1 million person-years, with a prevalence of 263 per 1 million people, and the numbers have been stable over the past few decades.
Increase in Use of Immunoglobulins Bolsters North America Intravenous Immunoglobulins Market
Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is rising with the surging use of these antibodies for treating various conditions.
Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the leading companies operating in the intravenous immunoglobulin market.
A few of the major primary and secondary sources referred to while preparing the report on the North America intravenous immunoglobulin market are the Myasthenia Gravis Foundation of America, Journal of Allergy and Clinical Immunology, Genetic and Rare Diseases Information Center, Immune Deficiency Foundation, GBS Foundation, Centers for Disease Control and Prevention
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Intravenous Immunoglobulin Market, by Geography
2.2 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. INTRAVENOUS IMMUNOGLOBULIN MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. INTRAVENOUS IMMUNOGLOBULIN MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Increase in Use of Immunoglobulins
5.1.2 Rising Immunodeficiency Disease Prevalence
5.2 Market Restraints
5.2.1 High Cost of Therapy
5.3 Market Opportunities
5.3.1 New Product Launches and Approvals
5.4 Future Trends
5.4.1 Strong Pipeline of IVIG Candidates
5.5 Impact Analysis:
6. INTRAVENOUS IMMUNOGLOBULIN MARKET – NORTH AMERICA MARKET ANALYSIS
6.1 Intravenous Immunoglobulin Market Revenue (US$ Mn), 2022 – 2030
7. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
7.1 Overview
7.2 Intravenous Immunoglobulin Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 IgG
7.3.1 Overview
7.3.2 IgG: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.4 IgA
7.4.1 Overview
7.4.2 IgA: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.5 IgM
7.5.1 Overview
7.5.2 IgM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
8.1 Overview
8.2 Intravenous Immunoglobulin Market Revenue Share, by Application, 2022 & 2030 (%)
8.3 Immunodeficiency Diseases
8.3.1 Overview
8.3.2 Immunodeficiency Diseases: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy
8.4.1 Overview
8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Idiopathic Thrombocytopenic Purpura
8.5.1 Overview
8.5.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Multifocal Motor Neuropathy
8.6.1 Overview
8.6.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Hypogammaglobulinemia
8.7.1 Overview
8.7.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Guillain-Barre Syndrome
8.8.1 Overview
8.8.2 Guillain-Barre Syndrome: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.9 Specific Antibody Deficiency
8.9.1 Overview
8.9.2 Specific Antibody Deficiency: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.10 Inflammatory Myopathies
8.10.1 Overview
8.10.2 Inflammatory Myopathies: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.11 Myasthenia Gravis
8.11.1 Overview
8.11.2 Myasthenia Gravis: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY DISTRIBUTION CHANNEL
9.1 Overview
9.2 Intravenous Immunoglobulin Market Revenue Share, by Route of Administration, 2022 & 2030 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
10.1 Overview
10.2 Intravenous Immunoglobulin Market Revenue Share, by Species, 2022 & 2030 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
11. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET - GEOGRAPHICAL ANALYSIS
11.1 North America Intravenous Immunoglobulin Market, Revenue and Forecast To 2030
11.1.1 Overview
11.1.2 North America Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.3 North America: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.4 North America: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.5 North America: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.6 North America: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7 North America Intravenous Immunoglobulin Market, by Country
11.1.7.1 US
11.1.7.1.1 Overview
11.1.7.1.2 US Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.1.3 US: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.1.4 US: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.1.5 US: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.1.6 US: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7.2 Canada
11.1.7.2.1 Overview
11.1.7.2.2 Canada Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.2.3 Canada: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.2.4 Canada: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.2.5 Canada: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.2.6 Canada: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7.3 Mexico
11.1.7.3.1 Overview
11.1.7.3.2 Mexico Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.3.3 Mexico: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.3.4 Mexico: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.3.5 Mexico: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.3.6 Mexico: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
12. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in North America Intravenous Immunoglobulin Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Takeda Pharmaceutical Co Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Grifols SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Octapharma AG
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Kedrion SpA
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 CSL Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 LFB Group
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About Us
14.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Intravenous Immunoglobulin Market, by Geography
2.2 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. INTRAVENOUS IMMUNOGLOBULIN MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. INTRAVENOUS IMMUNOGLOBULIN MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Increase in Use of Immunoglobulins
5.1.2 Rising Immunodeficiency Disease Prevalence
5.2 Market Restraints
5.2.1 High Cost of Therapy
5.3 Market Opportunities
5.3.1 New Product Launches and Approvals
5.4 Future Trends
5.4.1 Strong Pipeline of IVIG Candidates
5.5 Impact Analysis:
6. INTRAVENOUS IMMUNOGLOBULIN MARKET – NORTH AMERICA MARKET ANALYSIS
6.1 Intravenous Immunoglobulin Market Revenue (US$ Mn), 2022 – 2030
7. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
7.1 Overview
7.2 Intravenous Immunoglobulin Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 IgG
7.3.1 Overview
7.3.2 IgG: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.4 IgA
7.4.1 Overview
7.4.2 IgA: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.5 IgM
7.5.1 Overview
7.5.2 IgM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
8.1 Overview
8.2 Intravenous Immunoglobulin Market Revenue Share, by Application, 2022 & 2030 (%)
8.3 Immunodeficiency Diseases
8.3.1 Overview
8.3.2 Immunodeficiency Diseases: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy
8.4.1 Overview
8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Idiopathic Thrombocytopenic Purpura
8.5.1 Overview
8.5.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Multifocal Motor Neuropathy
8.6.1 Overview
8.6.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Hypogammaglobulinemia
8.7.1 Overview
8.7.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Guillain-Barre Syndrome
8.8.1 Overview
8.8.2 Guillain-Barre Syndrome: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.9 Specific Antibody Deficiency
8.9.1 Overview
8.9.2 Specific Antibody Deficiency: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.10 Inflammatory Myopathies
8.10.1 Overview
8.10.2 Inflammatory Myopathies: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.11 Myasthenia Gravis
8.11.1 Overview
8.11.2 Myasthenia Gravis: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY DISTRIBUTION CHANNEL
9.1 Overview
9.2 Intravenous Immunoglobulin Market Revenue Share, by Route of Administration, 2022 & 2030 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
10.1 Overview
10.2 Intravenous Immunoglobulin Market Revenue Share, by Species, 2022 & 2030 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
11. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET - GEOGRAPHICAL ANALYSIS
11.1 North America Intravenous Immunoglobulin Market, Revenue and Forecast To 2030
11.1.1 Overview
11.1.2 North America Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.3 North America: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.4 North America: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.5 North America: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.6 North America: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7 North America Intravenous Immunoglobulin Market, by Country
11.1.7.1 US
11.1.7.1.1 Overview
11.1.7.1.2 US Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.1.3 US: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.1.4 US: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.1.5 US: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.1.6 US: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7.2 Canada
11.1.7.2.1 Overview
11.1.7.2.2 Canada Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.2.3 Canada: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.2.4 Canada: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.2.5 Canada: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.2.6 Canada: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7.3 Mexico
11.1.7.3.1 Overview
11.1.7.3.2 Mexico Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.3.3 Mexico: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.3.4 Mexico: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.3.5 Mexico: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.3.6 Mexico: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
12. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET – INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in North America Intravenous Immunoglobulin Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Takeda Pharmaceutical Co Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Grifols SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Octapharma AG
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Kedrion SpA
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 CSL Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 LFB Group
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About Us
14.2 Glossary of Terms
